Professional
Added to YB: 2024-12-13
Pitch date: 2024-09-30
PHAT [bullish]
Phathom Pharmaceuticals, Inc.
-19.16%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
Market Cap
$1.0B
Pitch Price
$18.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.93
P/E
-3.88
EV/Sales
10.02
Sector
Pharmaceuticals
Category
growth
Show full summary:
PGIM Jennison Health Sciences Fund Portfolio Holding: Phathom Pharmaceuticals, Inc.
PHAT: Vonoprazan (Voquezna) for GERD, 1st new mechanism in 30+ yrs. Approved Nov '23 for erosive GERD, recently for non-erosive. Strong launch: robust payer coverage, FDA approval for larger NERD population, positive patient/physician feedback. Early stage, consensus underestimates potential.
Read full article (1 min)